FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology and represents an improved method of producing tagatose from saccharide, wherein the method comprises converting fructose-6-phosphate (F6P) to tagatose-6-phosphate (T6P) using fructose-6-phosphate epimerase (F6PE), wherein F6PE contains the amino acid sequence SEQ ID NO: 2 or SEQ ID NO: 7; and conversion of T6P to tagatose using tagatose-6-phosphate phosphatase (T6PP), where F6PE has higher activity in the improved method compared to the method in which F6PE from Dictyoglomus thermophilum with access number UniProt B5YBD7 is used.
EFFECT: invention enables to obtain tagatose with a high degree of efficiency.
16 cl, 7 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ENZYMATIC HEXOSE PRODUCTION | 2018 |
|
RU2766710C2 |
| MULTIMERIZING POLYPEPTIDES DERIVED FROM DOMAIN WITH ROLL-TYPE PENTONE BASE OF ADENOVIRUS | 2019 |
|
RU2820522C2 |
| COMPOSITIONS AND METHODS OF GENE EDITING | 2019 |
|
RU2804665C2 |
| ENZYMATIC PRODUCTION OF D-ALLULOSE | 2017 |
|
RU2819709C2 |
| MULTIFUNCTIONAL MULTI-SPECIFIC MULTIMERIC BIOMOLECULAR POLYMER WITH PROLONGED IN VIVO EFFICIENCY | 2020 |
|
RU2805307C1 |
| CHIMERIC PROTEIN L1 OF PAPILLOMAVIRUS | 2020 |
|
RU2808002C2 |
| POLYVALENT IMMUNOGENIC COMPOSITION AGAINST HUMAN PAPILLOMAVIRUS | 2020 |
|
RU2806424C2 |
| HYBRID NEUROTOXINS | 2017 |
|
RU2782382C2 |
| TARGETED GENE INTEGRATION OF NK INHIBITOR GENES FOR IMPROVED IMMUNE CELL THERAPY | 2018 |
|
RU2797304C2 |
| TUMOR-TARGETED AGONISTIC CD28-ANTIGEN-BINDING MOLECULES | 2019 |
|
RU2808030C2 |
